BridgeBio Pharma Inc (BBIO) — Cash Flow-to-Debt Ratio
BridgeBio Pharma Inc (BBIO) has a Cash Flow-to-Debt Ratio of -0.04x as of September 2025, meaning its operating cash flow of $-109.57 Million could theoretically repay 0% of its total liabilities ($2.92 Billion) in one year. See BridgeBio Pharma Inc free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
BridgeBio Pharma Inc Cash Flow-to-Debt Ratio (2017–2024)
Historical debt coverage capacity for BridgeBio Pharma Inc across 8 annual periods. Also explore BBIO year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for BridgeBio Pharma Inc (2017–2024)
Year-by-year debt coverage analysis for BridgeBio Pharma Inc. For market capitalisation and broader financial context, see BridgeBio Pharma Inc (BBIO) total market value.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.22x | $-520.73 Million | $2.38 Billion | ▲ +21.6% |
| 2023 | -0.28x | $-527.72 Million | $1.89 Billion | ▼ -24.4% |
| 2022 | -0.22x | $-419.49 Million | $1.87 Billion | ▲ +15.3% |
| 2021 | -0.27x | $-497.93 Million | $1.88 Billion | ▲ +60.5% |
| 2020 | -0.67x | $-399.71 Million | $595.70 Million | ▲ +58.8% |
| 2019 | -1.63x | $-253.59 Million | $155.70 Million | ▼ -575.1% |
| 2018 | -0.24x | $-136.64 Million | $566.44 Million | ▲ +9.0% |
| 2017 | -0.27x | $-40.49 Million | $152.73 Million | — |